Ack1

Activated Cdc42 kinase 1; TNK2

Ack1 (Activated Cdc42 kinase 1) is an enzyme that in humans is encoded by the TNK2 gene. Ack1 binds to multiple receptor tyrosine kinases e.g. EGFR, MERTK, AXL, HER2 and insulin receptor (IR). Ack1 also interacts with Cdc42Hs in its GTP-bound form and inhibits both the intrinsic and GTPase-activating protein (GAP)-stimulated GTPase activity of Cdc42Hs. Ack1 is a survival kinase and shown to be associated with tumor cell survival, proliferation, hormone-resistance and radiation resistance. Ack1 has emerged as a new cancer target and multiple small molecule inhibitors have been reported.

Ack1 Inhibitors

AIM-100

Cat. No.: HY-15290

AIM-100 is a potent and selective **Ack1** inhibitor with an **IC_{50}** of 21.58 nM. AIM-100 also inhibits Tyr^{267} phosphorylation. AIM-100 does not inhibits other kinases including PI3-kinase and AKT subfamily members. AIM-100 has an anticancer effect.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNF-7

Cat. No.: HY-10943

GNF-7 is a multikinase inhibitor. GNF-7 is a **Bcr-Abl** inhibitor, with **IC_{50}**s of 133 nM and 61 nM for $Bcr\text{-}Abl^{WT}$ and $Bcr\text{-}Abl^{T315I}$, respectively.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRCA-0008

Cat. No.: HY-12331

KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg